Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (6393K)
April 11 2018 - 12:15PM
UK Regulatory
TIDMHEMO
RNS Number : 6393K
Hemogenyx Pharmaceuticals PLC
11 April 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Director / PDMR Shareholding
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that on 9 April 2018 options to subscribe for
18,002,568 ordinary shares of GBP0.01 each in the Company
("Ordinary Shares" and the "Options") were granted to Professor Sir
Marc Feldmann, Chairman, Hemogenyx.
The Options were granted as part of a remuneration package. The
exercise price of the an Option is GBP0.035 per Option Share. The
Option Shares shall vest in 12 quarterly instalments in arrears on
and with effect from the first Vesting Date, being 30 June
2018.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- --------------------------------------------------------
a) Name Marc Feldmann
--- ----------------- -------------------------------------
2 Reason for the notification
--- --------------------------------------------------------
a) Position/status Chairman
--- ----------------- -------------------------------------
b) Initial Amendment to prior notifications
notification 00038962
/Amendment
--- ----------------- -------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- --------------------------------------------------------
a) Name Hemogenyx Pharmaceuticals PLC
--- ----------------- -------------------------------------
b) LEI 2138008L93GYU5GN6179
--- ----------------- -------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- --------------------------------------------------------
a) Description Grant of Option
of the
financial
instrument,
type of
instrument
Identification
code
--- ----------------- -------------------------------------
b) Nature Acceptance of a stock option granted
of the as part of a remuneration package
transaction
--- ----------------- -------------------------------------
c) Price(s) Price Volume
and volume(s) ------ ---------
0.035 18002568
------ ---------
--- ----------------- -------------------------------------
d) Date of 9 April 2018
the transaction
--- ----------------- -------------------------------------
e) Place Outside of a trading venue
of the
transaction
--- ----------------- -------------------------------------
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Sir Marc Feldmann, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930
Limited
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Tel: +44 (0)20 7933 8780 or
Investor Relations) hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
novel therapies and treatments for blood diseases such as leukemia
and lymphoma. The company's leading technologies aim to change the
way in which bone marrow/hematopoietic stem cell (BM/HSC)
transplants are performed and improve their efficacy. HemoGenyx's
two distinct and complementary products include an immunotherapy
product for patient conditioning-the CDX bi-specific antibody-and a
cell therapy product for BM/HSC transplantation-the HuPHEC. Each of
these products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBLGDSUBBBGIB
(END) Dow Jones Newswires
April 11, 2018 12:15 ET (16:15 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024